The main objective of our group is the study of genetic variability in drug (xenobiotic) metabolism and its role in susceptibility to therapeutic drugs and environmental agents. This variability is a major determining factor in the beneficial and adverse effects inchemical exposure.
Research concerns functional and mechanistic studies of drug metabolism enzyme variants to obtain insight in molecular mechanism of function of these enzymes, allowing the rationalization of their effect in exposure to agents and in specific disease states. We focus mainly on human cytochrome P450, one of the most important enzyme families in drug metabolism, using various in vitro models, and a pleiotropy of genetic and biochemical techniques.
This Action will:
The network will promote and coordinate a highly translational and innovative research program in Europe and beyond with the ultimate goal to pre-empt and prevent DILI, develop innovative therapeutic approaches that could improve clinical outcomes and enhance public awareness, while developing a forum for knowledge exchange and training of young European researches.Michel Kranendonk, the head of the Xenobiotic Metabolism lab, is member of the Management Committee of this Cost Action as well as member of the Workgroup 3.
Open-access publication:ADVANCED PRECLINICAL MODELS FOR EVALUATION OF DRUG INDUCED LIVER INJURY - CONSENSUS STATEMENT BY THE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK [PRO-EURO-DILI-NET] Checa et al. (2021) J Hepatol https://doi.org/10.1016/j.jhep.2021.06.021
The project had as goal to address these issues by:
The collaborative project between Lisbon and Toulouse (INSA) addressed these issues using both soluble purified (Partner 1, Toulouse) and membrane bound CPR forms (Partner 2 Lisbon).Several critical residues in a specific segment of the CPR protein, the hinge region could be identified in the open-closed dynamics of CPR, in which ionic strength seems to play a role. This extensive protein dynamics is responsible for the formation of an ensemble of open CPR conformers, by which CPR can interact with so many structurally different redox partners. Moreover, it was demonstrated that each redox partner (i.e. CYPs) interact with CPR via the use of specific biding-motifs of the interaction surface, the FMN domain, in an isoform specific manner. Additionally, we found that the substrate bound by CYP influences this interaction.
Team Members:Bernardo Brito Palma, Bruno Costa Gomes, Francisco Esteves, Diana Campelo
Esteves F, et al. Interaction Modes of Microsomal Cytochrome P450s with Its Reductase and the Role of Substrate Binding. Int. J. Mol. Sci. 2020 Sep 11;21(18):6669. doi: 10.3390/ijms21186669
Esteves F, etal. The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions with Structurally Diverse Redox Partners. Frontiers Pharmacol. 2020 Mar 18;11:299. doi: 10.3389/fphar.2020.00299
Campelo D, et al. Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450. Int. J. Mol. Sci. 2018 Dec 6;19(12):3914. doi: 10.3390/ijms19123914
Quast RB. et al., Accurate Determination of Human CPR Conformational Equilibrium by smFRET Using Dual Orthogonal Noncanonical Amino Acid Labeling. Chembiochem. 2019 Mar 1;20(5):659-666. doi: 10.1002/cbic.201800607
Esteves F, et al. Human cytochrome P450 expression in bacteria: Whole-cell high-throughput activity assay for CYP1A2, 2A6 and 3A4. Biochem Pharmacol. 2018 Dec;158:134-140. doi: 10.1016/j.bcp.2018.10.006
Campelo D, et al. The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength. Frontiers Pharmacol. 2017 Oct 30;8:755. doi: 10.3389/fphar.2017.00755
Esteves F, et al. The Central Role of Cytochrome P450 in Xenobiotic Metabolism—A Brief Review on a Fascinating Enzyme Family. J.Xenobiot. 2021, 11, 94–114. https://doi.org/10.3390/jox11030007
Fernandez-Checa et al., ADVANCED PRECLINICAL MODELS FOR EVALUATION OF DRUG INDUCED LIVER INJURY - CONSENSUS STATEMENT BY THE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK [PRO-EURO-DILI-NET] J Hepatol. 2021; S0168-8278(21)00441-4. doi: 10.1016/j.jhep.2021.06.021 (open access)
Esteves F, Rueff J, Kranendonk M. The Central Role of Cytochrome P450 in Xenobiotic Metabolism-A Brief Review on a Fascinating Enzyme Family. J. Xenobiot. 2021; 11(3):94-114. doi: 10.3390/jox11030007 (open access)
Silveira, C.M., Rodrigues, P.R., Ghach, W., Pereira, S.A., Esteves, F., Kranendonk, M., Etienne, M., Almeida, M.G. Electrochemical Activity of Cytochrome P450 1A2: The Relevance of O2 Control and the Natural Electron Donor ChemElectroChem 2021, 8, 500–507. doi: 10.1002/celc.202001255
Esteves F, Urban P, Rueff J, Truan G, Kranendonk M. Interaction Modes of Microsomal Cytochrome P450s with Its Reductase and the Role of Substrate Binding. Int. J. Mol. Sci. 2020; 21(18):6669. doi: 10.3390/ijms21186669 (open access)
Esteves F, Campelo D, Gomes BC, Urban P, Bozonnet S, Lautier T, Rueff J, Truan G, Kranendonk M. The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions with Structurally Diverse Redox Partners. Frontiers Pharmacol. 2020; 299. doi: 10.3389/fphar.2020.00299 (open access)
Rueff J, Rodrigues AS, Kranendonk M. A personally guided tour on some of our data with the Ames assay-A tribute to Professor Bruce Ames. Mutat. Res. 2019 Oct;846:503094. doi: 10.1016/j.mrgentox.2019.503094.
Quast RB, Fatemi F, Kranendonk M, Margeat E, Truan G. Accurate Determination of Human CPR Conformational Equilibrium by smFRET Using Dual Orthogonal Noncanonical Amino Acid Labeling. Chembiochem. 2019;20(5):659-666. doi: 10.1002/cbic.201800607.
Esteves F, Campelo D, Urban P, Bozonnet S, Lautier T, Rueff J, Truan G, Kranendonk M. Human cytochrome P450 expression in bacteria: Whole-cell high-throughput activity assay for CYP1A2, 2A6 and 3A4. Biochem. Pharmacol. 2018, 158: 134-140. doi: 10.1016/j.bcp.2018.10.006
Amit V. Pandey, Colin J. Henderson, Yuji Ishii, Michel Kranendonk, Wayne L. Backes, Ulrich M. Zanger, Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function. Frontiers Research Topic ebook published in: Frontiers in Pharmacology (2018), by Frontiers Media SA (https://www.frontiersin.org/research-topics/4658/role-of-protein-protein-interactions-in-metabolism-genetics-structure-function) (open access)
Campelo D, Esteves F, Brito Palma B, Costa Gomes B, Rueff J, Lautier T, Urban P, Truan G, Kranendonk M. Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450. Int. J. Mol. Sci. 2018; 19(12):3914. doi: 10.3390/ijms19123914 (open access)
Campelo D, Lautier T, Urban P, Esteves F, Bozonnet S, Truan G, Kranendonk M. The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength. Frontiers Pharmacol. 2017; 8:755. doi: 10.3389/fphar.2017.00755 (open access)
McCammon KM, Panda SP, Xia C, Kim JJ, Moutinho D, Kranendonk M, Auchus RJ, Lafer EM, Ghosh D, Martasek P, Kar R, Masters BS, Roman LJ. Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype. J. Biol. Chem. 2016;291(39):20487-502. doi: 10.1074/jbc.M116.716019.
Palma BB, Moutinho D, Urban P, Rueff J, Kranendonk M. Cytochrome P450 expression system for high-throughput real-time detection of genotoxicity: Application to the study of human CYP1A2 variants. Mutat Res Genet Toxicol Environ Mutagen. 2016 806:24-33. doi: 10.1016/j.mrgentox.2016.06.004
Palma BB, Fisher CW, Rueff J, Kranendonk M. Prototype Systems Containing Human Cytochrome P450 for High-Throughput Real-Time Detection of DNA Damage by Compounds That Form DNA-Reactive Metabolites. Chem Res Toxicol. 2016; 29(5):747-56. doi: 10.1021/acs.chemrestox.5b00455.
Kranendonk M, Alves M, Antunes P, Rueff J. Human sulfotransferase 1A1-dependent mutagenicity of 12-hydroxy-nevirapine: the missing link? Chem Res Toxicol. 2014; 27(11):1967-71. doi: 10.1021/tx5003113.
Palma BB, Silva E Sousa M, Urban P, Rueff J, Kranendonk M. Functional characterization of eight human CYP1A2 variants: the role of cytochrome b5. Pharmacogenet Genomics. 2013; 23(2):41-52. doi: 10.1097/FPC.0b013e32835c2ddf
Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS, Kranendonk M. Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system. Drug Metab. Dispos. 2012;40(4):754-60. doi: 10.1124/dmd.111.042820.
Gómez-Bombarelli R, Palma BB, Martins C, Kranendonk M, Rodrigues AS, Calle E, Rueff J, Casado J Alkylating potential of oxetanes. . Chem Res Toxicol. 2010; 23(7):1275-81. doi: 10.1021/tx100153w
Palma BB, Silva E Sousa M, Vosmeer CR, Lastdrager J, Rueff J, Vermeulen NP, Kranendonk M. Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression. Pharmacogenomics J. 2010; 10(6):478-88. doi: 10.1038/tpj.2010.2.
Marohnic CC, Panda SP, McCammon K, Rueff J, Masters BS, Kranendonk M. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug Metab Dispos. 2010; 38(2):332-40. doi: 10.1124/dmd.109.030445.
Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, Masters BS, Rueff J. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch Biochem Biophys. 2008; 475(2):93-9. doi: 10.1016/j.abb.2008.04.014.
NOVA Medical SchoolCampo Mártires da Pátria, 1301169-056 LisboaPORTUGAL
GeralTel.: +351 218 803 000
Lista de Contactos
Associação de Estudantes
Notícias e Eventos
Prémios e Distinções